Treatment of ADHD: Guanfacine Extended Release in ADHD
Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR, <4 mg/d) adjunctive to a long-acting psychostimulant for ADHD continued in 461 subjects.
Saved in:
| Main Authors: | J Gordon Millichap, John J Millichap |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
2014-08-01
|
| Series: | Pediatric Neurology Briefs |
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
by: Huss M, et al.
Published: (2016-05-01) -
Guanfacine in Comorbid ADHD & Tourette’s Syndrome
by: J Gordon Millichap
Published: (1995-09-01) -
Guanfacine for the management of the behavioral manifestations of delirium in older hospitalized adults
by: Kayla Garvey, PharmD, et al.
Published: (2025-06-01) -
Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder
by: Bekir Yükcü, et al.
Published: (2025-02-01) -
Case series: Potential use of guanfacine for safer management of behavioral disturbances in patients with dementia
by: Jeong Hoo Lee, et al.
Published: (2025-06-01)